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Previewsbut also for the induction of strong anti-
body responses.
The study by Haniffa et al. will be
a landmark in the quest for the identifica-
tion and functional characterization of
DC subsets in human nonlymphoid
organs and their draining lymph nodes. It
significantly advanced the model of DC
subset classification across species and
tissues previously proposed (Guilliams
et al., 2010). It will help the effort put
forward by international experts to
define an official nomenclature for these
cell types (Ziegler-Heitbrock et al., 2010;
Figure 1). Last but not least, the dis-
covery of professional cross-presenting
CD141hiCLEC9A+XCR1+ DCs in human
skin has major implications for the clinic,
given that targeting of these cells for
vaccination purposes could be achieved
through intradermal administration as
a convenient and physiological route for
the delivery of antigen and adjuvant. Ascompared to systemic vaccination, this
strategy might allow decreasing of the
doses required to induce immunity,
and hence reduce side effects, while
facilitating the development of mucosal
immunity.REFERENCES
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The mechanisms linking skin inflammation and observed defects in skin barrier function and integrity need
further elucidation. In this issue of Immunity, Lai et al. (2012) identify REG3A as a downstream mediator of
interleukin 17A that enhances keratinocyte proliferation and downmodulates keratinocyte differentiation.Psoriasis (psoriasis vulgaris) is a chronic
inflammatory disease of the skin charac-
terized by the presence of raised ery-
thematous scaly plaques (see Nestle
et al. [2009] for a review). Histological
examination of the skin of patients with
psoriasis reveals inflammatory cellular
infiltrates in the dermis and a thickened
hyperproliferative epidermis. The kerati-
nocytes in the epidermis exhibit aberrant
maturation, with an increased rate of
mitosis for the basal keratinocytes, and
an incomplete cornification of the kerati-
nocytes that form the uppermost epi-
dermal layer. The inflammatory infiltrateincludes plasmacytoid dendritic cells,
macrophages, neutrophils, and T cells
that express T helper-1 (Th1) and T
helper-17 (Th17) cell-derived cytokines.
Th17 cell responses have been linked
to psoriasis by human genetic and clinical
studies. Th17 cells express the IL-23
receptor, and IL-23 is critical for mainte-
nance of the Th17 cell phenotype and
for expansion of Th17 cell populations
(Miossec et al., 2009), and variations in
the genes encoding the shared p40
subunit of IL-12 and IL-23 and the IL-23
receptor have been associated with
susceptibility to psoriasis (see Nestleet al. [2009]). Blockade of IL-12 and IL-
23 with ustekinumab, which targets the
shared p40 subunit of these cytokines,
in psoriasis patients improves disease
scores, implicating Th1- and/or Th17 cell-
derived cytokines in disease pathology
(Nestle et al., 2009).
Th17 cells express both IL-17A and
IL-17F, which can form either homo-
dimers or heterodimers, and can bind to
the IL-17 receptor complex comprised
of IL-17 receptor A (IL17RA) and IL-17
receptor C (IL17RC) to signal to cells
(Miossec et al., 2009). Recent clinical
studies evaluating the blockade ofnity 37, July 27, 2012 ª2012 Elsevier Inc. 5
Figure 1. Keratinocyte Responses to Th17 Cytokines
Lymphocytes activated by dendritic cells infiltrate inflamed skin and express IL-22 and IL-17. IL-22 can
directly act on keratinocytes to enhance proliferation and inhibit keratinocyte terminal differentiation. IL-
22 also induces the expression of antimicrobial peptides from keratinocytes. IL-17 acts on keratinocytes
and induces the expression of antimicrobial peptides and chemokines that recruit lymphocytes and
neutrophils into the inflamed skin. IL-17 and IL-22 synergize for more robust responses. Lai et al. (2012)
demonstrate that IL-17 induces the expression of REG3A and that keratinocytes respond directly
to REG3A with increased proliferation and migration. REG3A also directly inhibits the terminal differenti-
ation of keratinocytes. The image schematically represents skin inflammation as in psoriasis. Blue
cells represent lymphocytes, purple cells represent neutrophils, and the green cell is a dendritic cell.
Tan cells represent keratinocytes, with proliferating cells represented by the yellow color, and differenti-
ation is represented by changes to the square shape. Green dots represent chemokines and blue squig-
gles represent antimicrobial peptides. Thank you to D.H. Potter for creating the figure.
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2012) or the blockade of IL-17RA with
brodalumab (Papp et al., 2012) clearly
implicate the IL-17 pathway as contrib-
uting to pathology in psoriasis and sup-
port a specific and nonredundant role
for IL-17A in this disease. Treatment of
psoriasis patients with these agents
results in significant improvements in
clinical scores as well as improvements
in the status of limited biomarkers in the
skin (Leonardi et al., 2012; Papp et al.,
2012).
How does IL-17A contribute to the
characteristic skin pathology in psoriasis?
Keratinocytes can respond to inflamma-
tory cytokines, including IL-17A, IL-17F,
IL-17AF heterodimer, IL-22, tumor ne-
crosis factor-a (TNF-a), and interferons,
by producing their own inflammatory
mediators and by altering proliferation
and maturation. Each cytokine induces
a discrete set of downstream genes,
consistent with the unique signaling
pathways coupled to the cytokine recep-
tors. IL-17A induces the expression of
antimicrobial peptides and chemokines
from keratinocytes, including chemo-
kines associated with recruitment of neu-
trophils (CXCL1, CXCL3, CXCL5, CXCL6,6 Immunity 37, July 27, 2012 ª2012 Elsevierand CXCL8) and Th17 cells (CCL20) into
psoriatic skin (Nograles et al., 2008).
In the clinical studies targeting the IL-17
pathway, blockade of the IL-17 receptor
(IL-17RA) with brodalumab results in a
normalization of keratinocyte maturation
and mitotic activity (Papp et al., 2012).
This suggests that signals through the
IL-17RA can alter keratinocyte prolifera-
tion and maturation. The question is
whether this is a direct effect of IL-17,
and if not, how it is mediated.
In this issue of Immunity, Lai et al. (2012)
identifyREG3A (regenerating islet-derived
protein 3 alpha) as a potential link
between cells that produce IL-17 and
the hyperproliferative response of psori-
atic keratinocytes (Figure 1). REG3A is
a member of the Reg family of secreted
proteins (see Parikh et al., 2012 for a
review). Reg proteins are C-type lectin-
like proteins that have been associated
with cellular proliferative responses. In
humans and mice, there are four sub-
types of Reg proteins, with multiple
members in some subtypes (Parikh et al.,
2012). Human proteins are designated
with uppercase names (ie, REG3A) and
rodent orthologs are denoted with lower-
case names (ie, Reg3g).Inc.Reg proteins have been linked to Th17
cell-derived cytokine responses in the
digestive system. Previous studies have
shown that Reg proteins are induced in
mouse colon after C. rodentium infection
and that induction of Reg proteins is
dependent on IL-22 (Zheng et al., 2008).
IL-22-deficient mice do not produce Reg
proteins after infection and also exhibit
decreased survival after C. rodentium
infection. Administration of Reg3g to
IL-22-deficient mice provides a partial
rescue under these conditions, demon-
strating a clear in vivo role for Reg3g
induced by IL-22 (Zheng et al., 2008).
In this issue, Lai et al. (2012) show that
IL-17A can induce the expression of
REG3A in human keratinocytes and that
REG3A can act on keratinocytes to
augment their proliferation. In contrast
to the observations of Zheng et al.
(2008) in which IL-22 was reported to
be required for induction of Reg3g from
mouse colonic epithelium, IL-22 did not
directly induce REG3A expression from
human keratinocytes, although IL-22
enhanced the induction of REG3A by
IL-17A.
Lai et al. (2012) demonstrate that imi-
quimod treatment of the skin of mice,
which induces a Th17 cell-dependent
skin inflammatory response, also induces
expression of Reg3g, as does wounding
of the skin. IL-22 is also produced in
response to imiquimod in mice, and
a recent study demonstrates that IL-17A,
IL-17F, and IL-22 each contribute to the
skin response in this model (Pantelyushin
et al., 2012). This suggests that the
IL-17A-mediated induction of Reg3g is
not redundant with the role that IL-22 is
playing in response to imiquimod.
REG3A appears to signal through
receptor complexes and signaling path-
ways that are quite distinct from the
canonical JAK kinase and activated
STAT protein signaling used by the IL-22
receptor. Lai et al. (2012) have provided
data to support the role of EXTL3 as
a receptor for REG3A on keratinocytes.
EXTL3 (exostosin-like 3), a type II trans-
membrane protein, has been identified
as a high-affinity receptor for REG3A,
with a Kd of 4.41 nM for the interaction
between cell membrane rat EXTL3 and
soluble rat REG3A (see Parikh et al.,
2012 for review). Lai et al. (2012) find
that REG3A induced the phosphorylation
of the kinase AKT in keratinocytes, which
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kinase (PI3K) inhibitors. AKT phosphory-
lation was dependent upon expression
of EXTL3, implicating this protein in
REG3A responses. EXTL3 has been
proposed previously to be a glycosyl-
transferase with a role in heparin sulfate
chain elongation (Parikh et al., 2012).
Further characterization of EXTL3 is
necessary for determining whether the
proposed role in heparin sulfate chain
elongation is a key attribute of this protein
and whether this function plays a role in
the response to REG3A.
A key question that remains is how the
effects of IL-17 and REG3A are distinct
from those of IL-22 and related family
members on keratinocytes. REG3A
increased keratinocyte proliferation and
suppressed the expression of genes
associated with terminal differentiation
of keratinocytes, including loricrin, keratin
10, keratin 5, and filaggrin (Lai et al.,
2012). Yet IL-22 can also induce prolifera-
tion and production of antimicrobial
peptides and chemokines from keratino-
cytes. IL-22 and IL-17 can have additive
or synergistic effects in induction of
inflammatory mediators from keratino-
cytes, and both cytokines can downregu-
late skin barrier proteins such as loricrin
and keratin 10, consistent with the skin
barrier deficits seen in inflammatory
states (Nograles et al., 2008). However,
inflammatory T cells in psoriatic lesions
often express either IL-17 or IL-22, sug-
gesting that these T cell subpopulations
could mediate distinct effects. In animal
models, IL-22 can enhance antimicrobial
peptide and proinflammatory cytokine
gene expression and keratinocyte hyper-
plasia in the skin (Ma et al., 2008). IL-22
treatment of human keratinocytes inhibits
the production of transcripts encoding
fillagrin, keratin 1, and CALML5, which
are part of the keratinocyte terminaldifferentiation pathway (Nograles et al.,
2008). Additionally, IL-22, but not IL-17A,
is known to induce changes in human
skin explants that resembled psoriatic
skin changes, including a thickening of
the epidermis accompanied by down-
ward epidermal projections, and aberrant
mitotic responses of keratinocytes
(Nograles et al., 2008). These and other
data have suggested that IL-22, rather
than IL-17A, may be the primary mediator
of the aberrant keratinocyte differentia-
tion associated with psoriatic plaques.
The question is whether there are
two separate programs for keratinocyte
responses, IL-17A and REG3A as com-
pared with IL-22, with unique roles in
maintenance and repair of normal skin
integrity, or whether these pathways
represent coordinated aspects of a unified
response.
Does REG3A play a role in psoriasis?
REG3A mRNA was found to be elevated
in psoriatic skin lesions as compared
with normal skin, but was variably ex-
pressed in nonlesional skin from psorasis
patients (Lai et al., 2012). The authors
postulate a dependence upon the popula-
tions examined, but other explanations
must also be considered, including
possible variations in treatment regimens
or other parameters of disease for the
patient groups studied in this paper. An
alternative possibility is that there may
be distinct mechanisms for regulation of
REG3A production that are exhibited
among patients. Elevation of REG3A has
not been reported in all studies that
examine gene expression in keratinocytes
or psoriatic skin, and the reasons for this
are not clear. REG3A was not elevated in
the skin of patients with atopic dermatitis
(Lai et al., 2012), ruling out a general
induction of REG3A in skin inflammation.
It will be interesting to evaluate the levels
of REG3A expression in the respondingImmuskin of psoriasis patients treated with
agents that target the IL-17 pathway and
the IL-23 and IL-12 pathways. Further-
more, it will be important to understand
the systemic impact of alterations in
REG3A levels in various tissues as we
advance therapeutic agents that modu-
late Th17 cells and their mediators in
human disease. How the reg proteins
are themselves regulated will be the next
question as functional data emerge link-
ing reg proteins with Th17-cell mediated
responses.
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